nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexrazoxane—TOP2A—breast cancer	0.367	1	CbGaD
Dexrazoxane—TOP2A—Idarubicin—breast cancer	0.205	0.51	CbGbCtD
Dexrazoxane—TOP2A—Mitoxantrone—breast cancer	0.0881	0.219	CbGbCtD
Dexrazoxane—TOP2A—Epirubicin—breast cancer	0.0713	0.177	CbGbCtD
Dexrazoxane—TOP2A—Doxorubicin—breast cancer	0.0379	0.0942	CbGbCtD
Dexrazoxane—TOP2B—mammary gland—breast cancer	0.00371	0.108	CbGeAlD
Dexrazoxane—TOP2B—nipple—breast cancer	0.00307	0.0896	CbGeAlD
Dexrazoxane—TOP2B—embryo—breast cancer	0.00254	0.0739	CbGeAlD
Dexrazoxane—TOP2A—nipple—breast cancer	0.00226	0.0659	CbGeAlD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MTDH—breast cancer	0.00191	0.0803	CbGpPWpGaD
Dexrazoxane—TOP2B—endometrium—breast cancer	0.00186	0.0541	CbGeAlD
Dexrazoxane—TOP2B—uterus—breast cancer	0.00171	0.0499	CbGeAlD
Dexrazoxane—TOP2B—pituitary gland—breast cancer	0.00168	0.049	CbGeAlD
Dexrazoxane—TOP2B—adipose tissue—breast cancer	0.00167	0.0488	CbGeAlD
Dexrazoxane—TOP2B—female reproductive system—breast cancer	0.00154	0.0448	CbGeAlD
Dexrazoxane—TOP2B—adrenal gland—breast cancer	0.0015	0.0437	CbGeAlD
Dexrazoxane—TOP2B—bone marrow—breast cancer	0.00145	0.0423	CbGeAlD
Dexrazoxane—TOP2B—female gonad—breast cancer	0.0014	0.0408	CbGeAlD
Dexrazoxane—TOP2A—endometrium—breast cancer	0.00136	0.0398	CbGeAlD
Dexrazoxane—TOP2B—Topotecan—Irinotecan—breast cancer	0.00131	0.347	CbGdCrCtD
Dexrazoxane—TOP2B—endocrine gland—breast cancer	0.0013	0.0379	CbGeAlD
Dexrazoxane—TOP2A—uterus—breast cancer	0.00126	0.0367	CbGeAlD
Dexrazoxane—TOP2A—adipose tissue—breast cancer	0.00123	0.0359	CbGeAlD
Dexrazoxane—TOP2A—adrenal gland—breast cancer	0.0011	0.0322	CbGeAlD
Dexrazoxane—TOP2A—bone marrow—breast cancer	0.00107	0.0311	CbGeAlD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—RRAD—breast cancer	0.00104	0.0436	CbGpPWpGaD
Dexrazoxane—TOP2A—female gonad—breast cancer	0.00103	0.03	CbGeAlD
Dexrazoxane—TOP2B—lymph node—breast cancer	0.000899	0.0262	CbGeAlD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—breast cancer	0.00072	0.0302	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—CENPF—breast cancer	0.000702	0.0295	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—UBE2C—breast cancer	0.000674	0.0283	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT14—breast cancer	0.000669	0.0281	CbGpPWpGaD
Dexrazoxane—TOP2A—lymph node—breast cancer	0.000661	0.0193	CbGeAlD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—UBE2C—breast cancer	0.000639	0.0268	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MRE11A—breast cancer	0.000464	0.0195	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—GPX2—breast cancer	0.000452	0.019	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—AURKA—breast cancer	0.00044	0.0185	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—BARD1—breast cancer	0.000409	0.0172	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RB1CC1—breast cancer	0.000379	0.0159	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—CCNE1—breast cancer	0.000363	0.0153	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—breast cancer	0.000343	0.0144	CbGpPWpGaD
Dexrazoxane—TOP2A—G0 and Early G1—E2F1—breast cancer	0.000341	0.0143	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—STMN1—breast cancer	0.000327	0.0137	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—PER3—breast cancer	0.000325	0.0136	CbGpPWpGaD
Dexrazoxane—TOP2A—Docetaxel—Paclitaxel—breast cancer	0.000297	0.0788	CbGdCrCtD
Dexrazoxane—TOP2A—G0 and Early G1—CDK2—breast cancer	0.000295	0.0124	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—FASN—breast cancer	0.000292	0.0123	CbGpPWpGaD
Dexrazoxane—TOP2A—Gefitinib—Lapatinib—breast cancer	0.000291	0.0772	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—NR2F6—breast cancer	0.000276	0.0116	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TFF1—breast cancer	0.000245	0.0103	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—NOTCH1—breast cancer	0.000238	0.00999	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 1—APC—breast cancer	0.000233	0.00977	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—breast cancer	0.000226	0.00951	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CLDN4—breast cancer	0.000225	0.00945	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—ATF4—breast cancer	0.000225	0.00945	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—breast cancer	0.000219	0.00919	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—HES1—breast cancer	0.000214	0.00899	CbGpPWpGaD
Dexrazoxane—TOP2A—Topotecan—Irinotecan—breast cancer	0.000211	0.056	CbGdCrCtD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NRG1—breast cancer	0.000209	0.00878	CbGpPWpGaD
Dexrazoxane—TOP2A—Vindesine—Vinorelbine—breast cancer	0.000189	0.0501	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—DNMT1—breast cancer	0.000188	0.00788	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NRIP1—breast cancer	0.000178	0.00747	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NME1—breast cancer	0.000178	0.00746	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STMN1—breast cancer	0.000174	0.00732	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—breast cancer	0.000169	0.00708	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—breast cancer	0.000162	0.00679	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MRE11A—breast cancer	0.000151	0.00634	CbGpPWpGaD
Dexrazoxane—TOP2A—Vindesine—Vinblastine—breast cancer	0.000151	0.04	CbGdCrCtD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—CTNNB1—breast cancer	0.00015	0.00629	CbGpPWpGaD
Dexrazoxane—TOP2A—Paclitaxel—Docetaxel—breast cancer	0.000148	0.0393	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FST—breast cancer	0.000147	0.00618	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—ABL1—breast cancer	0.000138	0.00581	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—breast cancer	0.000134	0.00563	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—breast cancer	0.000132	0.00553	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RARB—breast cancer	0.000128	0.00539	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—E2F1—breast cancer	0.000126	0.00529	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—breast cancer	0.000125	0.00526	CbGpPWpGaD
Dexrazoxane—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—breast cancer	0.000125	0.00523	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—AHR—breast cancer	0.000123	0.00518	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—MYC—breast cancer	0.000121	0.0051	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—EGFR—breast cancer	0.000119	0.00499	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RAD51—breast cancer	0.000117	0.00491	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—breast cancer	0.000112	0.00471	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—breast cancer	0.000112	0.00469	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CPT1A—breast cancer	0.00011	0.00462	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ACHE—breast cancer	0.000109	0.00457	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK2—breast cancer	0.000109	0.00456	CbGpPWpGaD
Dexrazoxane—TOP2A—Epirubicin—Idarubicin—breast cancer	0.000108	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Idarubicin—breast cancer	0.000108	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Idarubicin—breast cancer	0.000108	0.0287	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—breast cancer	0.000103	0.00431	CbGpPWpGaD
Dexrazoxane—TOP2A—Vincristine—Vinorelbine—breast cancer	0.000102	0.027	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—THBS1—breast cancer	0.000102	0.00426	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP7—breast cancer	0.000102	0.00426	CbGpPWpGaD
Dexrazoxane—TOP2A—Gastric Cancer Network 2—TP53—breast cancer	9.97e-05	0.00419	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—breast cancer	9.69e-05	0.00407	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinorelbine—Vinblastine—breast cancer	9.52e-05	0.0253	CbGdCrCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCNE1—breast cancer	9.43e-05	0.00396	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NCOA2—breast cancer	9.43e-05	0.00396	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—EZH2—breast cancer	9.3e-05	0.00391	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—TYMS—breast cancer	9.26e-05	0.00389	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PAK1—breast cancer	8.98e-05	0.00377	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—breast cancer	8.98e-05	0.00377	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RB1—breast cancer	8.92e-05	0.00375	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—E2F1—breast cancer	8.86e-05	0.00372	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—breast cancer	8.71e-05	0.00366	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RAD51C—breast cancer	8.63e-05	0.00362	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—SYNE1—breast cancer	8.63e-05	0.00362	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGR1—breast cancer	8.4e-05	0.00353	CbGpPWpGaD
Dexrazoxane—TOP2A—Vinblastine—Vinorelbine—breast cancer	8.19e-05	0.0217	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STK11—breast cancer	8.16e-05	0.00343	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA1—breast cancer	8.16e-05	0.00343	CbGpPWpGaD
Dexrazoxane—TOP2A—Vincristine—Vinblastine—breast cancer	8.14e-05	0.0216	CbGdCrCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—EGR1—breast cancer	8.07e-05	0.00339	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AR—breast cancer	7.94e-05	0.00333	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PDGFA—breast cancer	7.66e-05	0.00322	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK2—breast cancer	7.64e-05	0.00321	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—breast cancer	7.61e-05	0.0032	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—breast cancer	7.58e-05	0.00318	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CENPF—breast cancer	7.52e-05	0.00316	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—breast cancer	7.38e-05	0.0031	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABL1—breast cancer	7.38e-05	0.0031	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—STAT5A—breast cancer	7.38e-05	0.0031	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SIRT1—breast cancer	7.23e-05	0.00304	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDK4—breast cancer	7.22e-05	0.00303	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—UBE2C—breast cancer	7.22e-05	0.00303	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—breast cancer	7.15e-05	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SMAD4—breast cancer	7.15e-05	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ABCB1—breast cancer	7.15e-05	0.003	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—breast cancer	7.02e-05	0.00295	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1B—breast cancer	6.95e-05	0.00292	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—SIRT1—breast cancer	6.95e-05	0.00292	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PLA2G4A—breast cancer	6.94e-05	0.00291	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGF1—breast cancer	6.86e-05	0.00288	CbGpPWpGaD
Dexrazoxane—TOP2A—Methyltestosterone—Fluoxymesterone—breast cancer	6.85e-05	0.0182	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BAX—breast cancer	6.76e-05	0.00284	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—TYMS—breast cancer	6.74e-05	0.00283	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CENPF—breast cancer	6.72e-05	0.00282	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—E2F1—breast cancer	6.71e-05	0.00282	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NCOR1—breast cancer	6.66e-05	0.0028	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—breast cancer	6.63e-05	0.00278	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MRE11A—breast cancer	6.54e-05	0.00275	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—FOXM1—breast cancer	6.52e-05	0.00274	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—UBE2C—breast cancer	6.45e-05	0.00271	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—breast cancer	6.41e-05	0.00269	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—RB1—breast cancer	6.28e-05	0.00264	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HIST1H2BC—breast cancer	6.27e-05	0.00263	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HIST1H2BK—breast cancer	6.27e-05	0.00263	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—FGFR1—breast cancer	5.94e-05	0.00249	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—FOXM1—breast cancer	5.83e-05	0.00245	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK2—breast cancer	5.79e-05	0.00243	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—HIST1H2BC—breast cancer	5.61e-05	0.00236	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—HIST1H2BK—breast cancer	5.61e-05	0.00236	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—breast cancer	5.49e-05	0.00231	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—LEP—breast cancer	5.48e-05	0.0023	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—breast cancer	5.47e-05	0.0023	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—breast cancer	5.45e-05	0.00229	CbGpPWpGaD
Dexrazoxane—TOP2A—Cytarabine—Gemcitabine—breast cancer	5.35e-05	0.0142	CbGdCrCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—NFKBIA—breast cancer	5.32e-05	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—MYC—breast cancer	5.32e-05	0.00223	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—CDK4—breast cancer	5.25e-05	0.00221	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—APC—breast cancer	5.15e-05	0.00216	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—NOS2—breast cancer	5.11e-05	0.00214	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGF—breast cancer	5.09e-05	0.00214	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—RAD51—breast cancer	5.06e-05	0.00212	CbGpPWpGaD
Dexrazoxane—TOP2A—Daunorubicin—Epirubicin—breast cancer	4.96e-05	0.0132	CbGdCrCtD
Dexrazoxane—TOP2A—Doxorubicin—Epirubicin—breast cancer	4.96e-05	0.0132	CbGdCrCtD
Dexrazoxane—TOP2A—Idarubicin—Epirubicin—breast cancer	4.96e-05	0.0132	CbGdCrCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1B—breast cancer	4.89e-05	0.00205	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP8—breast cancer	4.8e-05	0.00201	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—breast cancer	4.72e-05	0.00198	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—AURKA—breast cancer	4.71e-05	0.00198	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—NBN—breast cancer	4.69e-05	0.00197	CbGpPWpGaD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CCND1—breast cancer	4.66e-05	0.00196	CbGpPWpGaD
Dexrazoxane—TOP2A—Idarubicin—Doxorubicin—breast cancer	4.59e-05	0.0122	CbGdCrCtD
Dexrazoxane—TOP2A—Epirubicin—Doxorubicin—breast cancer	4.59e-05	0.0122	CbGdCrCtD
Dexrazoxane—TOP2A—Daunorubicin—Doxorubicin—breast cancer	4.59e-05	0.0122	CbGdCrCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—CDKN1A—breast cancer	4.51e-05	0.00189	CbGpPWpGaD
Dexrazoxane—TOP2A—Norethindrone—Fluoxymesterone—breast cancer	4.47e-05	0.0119	CbGdCrCtD
Dexrazoxane—TOP2A—Retinoblastoma (RB) in Cancer—TP53—breast cancer	4.37e-05	0.00183	CbGpPWpGaD
Dexrazoxane—Nausea—Vinorelbine—breast cancer	4.3e-05	0.000254	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—SERPINE1—breast cancer	4.3e-05	0.00181	CbGpPWpGaD
Dexrazoxane—Asthenia—Irinotecan—breast cancer	4.29e-05	0.000253	CcSEcCtD
Dexrazoxane—Asthenia—Mitoxantrone—breast cancer	4.29e-05	0.000253	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	4.28e-05	0.000253	CcSEcCtD
Dexrazoxane—Cough—Capecitabine—breast cancer	4.27e-05	0.000253	CcSEcCtD
Dexrazoxane—Stomatitis—Epirubicin—breast cancer	4.26e-05	0.000251	CcSEcCtD
Dexrazoxane—Neutropenia—Doxorubicin—breast cancer	4.24e-05	0.00025	CcSEcCtD
Dexrazoxane—Decreased appetite—Paclitaxel—breast cancer	4.23e-05	0.00025	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—AURKA—breast cancer	4.21e-05	0.00177	CbGpPWpGaD
Dexrazoxane—Dry mouth—Docetaxel—breast cancer	4.21e-05	0.000249	CcSEcCtD
Dexrazoxane—Haemoglobin—Methotrexate—breast cancer	4.21e-05	0.000249	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Paclitaxel—breast cancer	4.21e-05	0.000248	CcSEcCtD
Dexrazoxane—Fatigue—Paclitaxel—breast cancer	4.2e-05	0.000248	CcSEcCtD
Dexrazoxane—Haemorrhage—Methotrexate—breast cancer	4.19e-05	0.000247	CcSEcCtD
Dexrazoxane—Asthenia—Gemcitabine—breast cancer	4.17e-05	0.000247	CcSEcCtD
Dexrazoxane—Myalgia—Capecitabine—breast cancer	4.17e-05	0.000246	CcSEcCtD
Dexrazoxane—Pain—Paclitaxel—breast cancer	4.17e-05	0.000246	CcSEcCtD
Dexrazoxane—Constipation—Paclitaxel—breast cancer	4.17e-05	0.000246	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	4.14e-05	0.000245	CcSEcCtD
Dexrazoxane—Discomfort—Capecitabine—breast cancer	4.12e-05	0.000243	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—HSP90AA1—breast cancer	4.12e-05	0.00173	CbGpPWpGaD
Dexrazoxane—Pruritus—Gemcitabine—breast cancer	4.12e-05	0.000243	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—BCL2—breast cancer	4.12e-05	0.00173	CbGpPWpGaD
Dexrazoxane—Nausea—Thiotepa—breast cancer	4.11e-05	0.000243	CcSEcCtD
Dexrazoxane—Infection—Docetaxel—breast cancer	4.1e-05	0.000242	CcSEcCtD
Dexrazoxane—Weight decreased—Doxorubicin—breast cancer	4.1e-05	0.000242	CcSEcCtD
Dexrazoxane—Diarrhoea—Irinotecan—breast cancer	4.09e-05	0.000241	CcSEcCtD
Dexrazoxane—Diarrhoea—Mitoxantrone—breast cancer	4.09e-05	0.000241	CcSEcCtD
Dexrazoxane—Dry mouth—Capecitabine—breast cancer	4.08e-05	0.000241	CcSEcCtD
Dexrazoxane—Agranulocytosis—Epirubicin—breast cancer	4.08e-05	0.000241	CcSEcCtD
Dexrazoxane—Pneumonia—Doxorubicin—breast cancer	4.06e-05	0.00024	CcSEcCtD
Dexrazoxane—Shock—Docetaxel—breast cancer	4.06e-05	0.00024	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—breast cancer	4.06e-05	0.0017	CbGpPWpGaD
Dexrazoxane—Nervous system disorder—Docetaxel—breast cancer	4.05e-05	0.000239	CcSEcCtD
Dexrazoxane—Pruritus—Fluorouracil—breast cancer	4.05e-05	0.000239	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Docetaxel—breast cancer	4.04e-05	0.000239	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—breast cancer	4.04e-05	0.0017	CbGpPWpGaD
Dexrazoxane—Infestation NOS—Doxorubicin—breast cancer	4.04e-05	0.000239	CcSEcCtD
Dexrazoxane—Infestation—Doxorubicin—breast cancer	4.04e-05	0.000239	CcSEcCtD
Dexrazoxane—Feeling abnormal—Paclitaxel—breast cancer	4.01e-05	0.000237	CcSEcCtD
Dexrazoxane—Skin disorder—Docetaxel—breast cancer	4.01e-05	0.000237	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—breast cancer	4e-05	0.00168	CbGpPWpGaD
Dexrazoxane—Gastrointestinal pain—Paclitaxel—breast cancer	3.98e-05	0.000235	CcSEcCtD
Dexrazoxane—Diarrhoea—Gemcitabine—breast cancer	3.98e-05	0.000235	CcSEcCtD
Dexrazoxane—Infection—Capecitabine—breast cancer	3.97e-05	0.000235	CcSEcCtD
Dexrazoxane—Dizziness—Irinotecan—breast cancer	3.95e-05	0.000233	CcSEcCtD
Dexrazoxane—Haemoglobin—Epirubicin—breast cancer	3.94e-05	0.000233	CcSEcCtD
Dexrazoxane—Stomatitis—Doxorubicin—breast cancer	3.94e-05	0.000233	CcSEcCtD
Dexrazoxane—Anorexia—Docetaxel—breast cancer	3.94e-05	0.000233	CcSEcCtD
Dexrazoxane—Shock—Capecitabine—breast cancer	3.93e-05	0.000232	CcSEcCtD
Dexrazoxane—Nervous system disorder—Capecitabine—breast cancer	3.92e-05	0.000232	CcSEcCtD
Dexrazoxane—Haemorrhage—Epirubicin—breast cancer	3.92e-05	0.000232	CcSEcCtD
Dexrazoxane—Diarrhoea—Fluorouracil—breast cancer	3.91e-05	0.000231	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Capecitabine—breast cancer	3.91e-05	0.000231	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—breast cancer	3.91e-05	0.00164	CbGpPWpGaD
Dexrazoxane—Cardiac disorder—Methotrexate—breast cancer	3.89e-05	0.00023	CcSEcCtD
Dexrazoxane—Skin disorder—Capecitabine—breast cancer	3.88e-05	0.000229	CcSEcCtD
Dexrazoxane—Urticaria—Paclitaxel—breast cancer	3.87e-05	0.000229	CcSEcCtD
Dexrazoxane—Oedema peripheral—Epirubicin—breast cancer	3.86e-05	0.000228	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Epirubicin—breast cancer	3.85e-05	0.000228	CcSEcCtD
Dexrazoxane—Abdominal pain—Paclitaxel—breast cancer	3.85e-05	0.000227	CcSEcCtD
Dexrazoxane—Body temperature increased—Paclitaxel—breast cancer	3.85e-05	0.000227	CcSEcCtD
Dexrazoxane—TOP2A—Azacitidine—Gemcitabine—breast cancer	3.83e-05	0.0102	CbGdCrCtD
Dexrazoxane—Anorexia—Capecitabine—breast cancer	3.81e-05	0.000225	CcSEcCtD
Dexrazoxane—Angiopathy—Methotrexate—breast cancer	3.8e-05	0.000225	CcSEcCtD
Dexrazoxane—Vomiting—Irinotecan—breast cancer	3.8e-05	0.000224	CcSEcCtD
Dexrazoxane—Vomiting—Mitoxantrone—breast cancer	3.8e-05	0.000224	CcSEcCtD
Dexrazoxane—Dizziness—Fluorouracil—breast cancer	3.78e-05	0.000223	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Methotrexate—breast cancer	3.78e-05	0.000223	CcSEcCtD
Dexrazoxane—Agranulocytosis—Doxorubicin—breast cancer	3.77e-05	0.000223	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CHEK2—breast cancer	3.77e-05	0.00158	CbGpPWpGaD
Dexrazoxane—Musculoskeletal discomfort—Docetaxel—breast cancer	3.76e-05	0.000222	CcSEcCtD
Dexrazoxane—Headache—Irinotecan—breast cancer	3.74e-05	0.000221	CcSEcCtD
Dexrazoxane—Headache—Mitoxantrone—breast cancer	3.74e-05	0.000221	CcSEcCtD
Dexrazoxane—TOP2A—Mitotic G1-G1/S phases—MYC—breast cancer	3.74e-05	0.00157	CbGpPWpGaD
Dexrazoxane—Insomnia—Docetaxel—breast cancer	3.73e-05	0.000221	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1B—breast cancer	3.7e-05	0.00156	CbGpPWpGaD
Dexrazoxane—Alopecia—Methotrexate—breast cancer	3.7e-05	0.000219	CcSEcCtD
Dexrazoxane—Vomiting—Gemcitabine—breast cancer	3.7e-05	0.000219	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—HSP90AA1—breast cancer	3.68e-05	0.00155	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Docetaxel—breast cancer	3.68e-05	0.000217	CcSEcCtD
Dexrazoxane—Somnolence—Docetaxel—breast cancer	3.67e-05	0.000217	CcSEcCtD
Dexrazoxane—Mental disorder—Methotrexate—breast cancer	3.67e-05	0.000217	CcSEcCtD
Dexrazoxane—Malnutrition—Methotrexate—breast cancer	3.65e-05	0.000215	CcSEcCtD
Dexrazoxane—Erythema—Methotrexate—breast cancer	3.65e-05	0.000215	CcSEcCtD
Dexrazoxane—Haemoglobin—Doxorubicin—breast cancer	3.65e-05	0.000215	CcSEcCtD
Dexrazoxane—Headache—Gemcitabine—breast cancer	3.65e-05	0.000215	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Capecitabine—breast cancer	3.64e-05	0.000215	CcSEcCtD
Dexrazoxane—Cardiac disorder—Epirubicin—breast cancer	3.64e-05	0.000215	CcSEcCtD
Dexrazoxane—Vomiting—Fluorouracil—breast cancer	3.64e-05	0.000215	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CASP3—breast cancer	3.63e-05	0.00152	CbGpPWpGaD
Dexrazoxane—Haemorrhage—Doxorubicin—breast cancer	3.63e-05	0.000214	CcSEcCtD
Dexrazoxane—Insomnia—Capecitabine—breast cancer	3.62e-05	0.000214	CcSEcCtD
Dexrazoxane—Decreased appetite—Docetaxel—breast cancer	3.59e-05	0.000212	CcSEcCtD
Dexrazoxane—Headache—Fluorouracil—breast cancer	3.58e-05	0.000212	CcSEcCtD
Dexrazoxane—Oedema peripheral—Doxorubicin—breast cancer	3.57e-05	0.000211	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Docetaxel—breast cancer	3.56e-05	0.000211	CcSEcCtD
Dexrazoxane—Connective tissue disorder—Doxorubicin—breast cancer	3.56e-05	0.000211	CcSEcCtD
Dexrazoxane—Dyspnoea—Capecitabine—breast cancer	3.56e-05	0.000211	CcSEcCtD
Dexrazoxane—Fatigue—Docetaxel—breast cancer	3.56e-05	0.00021	CcSEcCtD
Dexrazoxane—Angiopathy—Epirubicin—breast cancer	3.56e-05	0.00021	CcSEcCtD
Dexrazoxane—Nausea—Mitoxantrone—breast cancer	3.55e-05	0.00021	CcSEcCtD
Dexrazoxane—Nausea—Irinotecan—breast cancer	3.55e-05	0.00021	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—breast cancer	3.53e-05	0.00148	CbGpPWpGaD
Dexrazoxane—Mediastinal disorder—Epirubicin—breast cancer	3.53e-05	0.000209	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—BRCA1—breast cancer	3.53e-05	0.00148	CbGpPWpGaD
Dexrazoxane—Constipation—Docetaxel—breast cancer	3.53e-05	0.000209	CcSEcCtD
Dexrazoxane—Pain—Docetaxel—breast cancer	3.53e-05	0.000209	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—breast cancer	3.53e-05	0.00148	CbGpPWpGaD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CTNNB1—breast cancer	3.5e-05	0.00147	CbGpPWpGaD
Dexrazoxane—Asthenia—Paclitaxel—breast cancer	3.5e-05	0.000206	CcSEcCtD
Dexrazoxane—Decreased appetite—Capecitabine—breast cancer	3.48e-05	0.000205	CcSEcCtD
Dexrazoxane—Alopecia—Epirubicin—breast cancer	3.46e-05	0.000205	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCNE1—breast cancer	3.46e-05	0.00145	CbGpPWpGaD
Dexrazoxane—Nausea—Gemcitabine—breast cancer	3.46e-05	0.000204	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Capecitabine—breast cancer	3.45e-05	0.000204	CcSEcCtD
Dexrazoxane—Fatigue—Capecitabine—breast cancer	3.45e-05	0.000204	CcSEcCtD
Dexrazoxane—Pruritus—Paclitaxel—breast cancer	3.45e-05	0.000204	CcSEcCtD
Dexrazoxane—Mental disorder—Epirubicin—breast cancer	3.43e-05	0.000203	CcSEcCtD
Dexrazoxane—Constipation—Capecitabine—breast cancer	3.42e-05	0.000202	CcSEcCtD
Dexrazoxane—Pain—Capecitabine—breast cancer	3.42e-05	0.000202	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—breast cancer	3.42e-05	0.00144	CbGpPWpGaD
Dexrazoxane—Malnutrition—Epirubicin—breast cancer	3.41e-05	0.000202	CcSEcCtD
Dexrazoxane—Erythema—Epirubicin—breast cancer	3.41e-05	0.000202	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—breast cancer	3.41e-05	0.00143	CbGpPWpGaD
Dexrazoxane—Feeling abnormal—Docetaxel—breast cancer	3.4e-05	0.000201	CcSEcCtD
Dexrazoxane—Nausea—Fluorouracil—breast cancer	3.4e-05	0.000201	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—TYMS—breast cancer	3.4e-05	0.00143	CbGpPWpGaD
Dexrazoxane—TOP2A—Circadian rythm related genes—JUN—breast cancer	3.38e-05	0.00142	CbGpPWpGaD
Dexrazoxane—Ill-defined disorder—Methotrexate—breast cancer	3.38e-05	0.0002	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Docetaxel—breast cancer	3.38e-05	0.000199	CcSEcCtD
Dexrazoxane—Anaemia—Methotrexate—breast cancer	3.37e-05	0.000199	CcSEcCtD
Dexrazoxane—Cardiac disorder—Doxorubicin—breast cancer	3.37e-05	0.000199	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK8—breast cancer	3.34e-05	0.0014	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Paclitaxel—breast cancer	3.33e-05	0.000197	CcSEcCtD
Dexrazoxane—Feeling abnormal—Capecitabine—breast cancer	3.29e-05	0.000195	CcSEcCtD
Dexrazoxane—Angiopathy—Doxorubicin—breast cancer	3.29e-05	0.000194	CcSEcCtD
Dexrazoxane—Malaise—Methotrexate—breast cancer	3.29e-05	0.000194	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—PTEN—breast cancer	3.27e-05	0.00137	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—H2AFX—breast cancer	3.27e-05	0.00137	CbGpPWpGaD
Dexrazoxane—Gastrointestinal pain—Capecitabine—breast cancer	3.27e-05	0.000193	CcSEcCtD
Dexrazoxane—Mediastinal disorder—Doxorubicin—breast cancer	3.27e-05	0.000193	CcSEcCtD
Dexrazoxane—Abdominal pain—Docetaxel—breast cancer	3.26e-05	0.000193	CcSEcCtD
Dexrazoxane—Body temperature increased—Docetaxel—breast cancer	3.26e-05	0.000193	CcSEcCtD
Dexrazoxane—Leukopenia—Methotrexate—breast cancer	3.26e-05	0.000193	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—E2F1—breast cancer	3.25e-05	0.00136	CbGpPWpGaD
Dexrazoxane—Dizziness—Paclitaxel—breast cancer	3.22e-05	0.00019	CcSEcCtD
Dexrazoxane—Alopecia—Doxorubicin—breast cancer	3.21e-05	0.000189	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—MAPK8—breast cancer	3.2e-05	0.00134	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—BRCA2—breast cancer	3.19e-05	0.00134	CbGpPWpGaD
Dexrazoxane—Cough—Methotrexate—breast cancer	3.18e-05	0.000188	CcSEcCtD
Dexrazoxane—Mental disorder—Doxorubicin—breast cancer	3.18e-05	0.000188	CcSEcCtD
Dexrazoxane—Urticaria—Capecitabine—breast cancer	3.18e-05	0.000188	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Epirubicin—breast cancer	3.17e-05	0.000187	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—breast cancer	3.16e-05	0.00133	CbGpPWpGaD
Dexrazoxane—Abdominal pain—Capecitabine—breast cancer	3.16e-05	0.000187	CcSEcCtD
Dexrazoxane—Body temperature increased—Capecitabine—breast cancer	3.16e-05	0.000187	CcSEcCtD
Dexrazoxane—Malnutrition—Doxorubicin—breast cancer	3.16e-05	0.000187	CcSEcCtD
Dexrazoxane—Erythema—Doxorubicin—breast cancer	3.16e-05	0.000187	CcSEcCtD
Dexrazoxane—Anaemia—Epirubicin—breast cancer	3.15e-05	0.000186	CcSEcCtD
Dexrazoxane—Myalgia—Methotrexate—breast cancer	3.1e-05	0.000183	CcSEcCtD
Dexrazoxane—Vomiting—Paclitaxel—breast cancer	3.1e-05	0.000183	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CCNE1—breast cancer	3.09e-05	0.0013	CbGpPWpGaD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.08e-05	0.000182	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—breast cancer	3.08e-05	0.00129	CbGpPWpGaD
Dexrazoxane—Malaise—Epirubicin—breast cancer	3.08e-05	0.000182	CcSEcCtD
Dexrazoxane—Discomfort—Methotrexate—breast cancer	3.07e-05	0.000181	CcSEcCtD
Dexrazoxane—Syncope—Epirubicin—breast cancer	3.06e-05	0.000181	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—BIRC5—breast cancer	3.05e-05	0.00128	CbGpPWpGaD
Dexrazoxane—Leukopenia—Epirubicin—breast cancer	3.05e-05	0.00018	CcSEcCtD
Dexrazoxane—Headache—Paclitaxel—breast cancer	3.05e-05	0.00018	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—TYMS—breast cancer	3.04e-05	0.00128	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Epirubicin—breast cancer	3e-05	0.000177	CcSEcCtD
Dexrazoxane—Cough—Epirubicin—breast cancer	2.98e-05	0.000176	CcSEcCtD
Dexrazoxane—Asthenia—Docetaxel—breast cancer	2.96e-05	0.000175	CcSEcCtD
Dexrazoxane—Infection—Methotrexate—breast cancer	2.96e-05	0.000175	CcSEcCtD
Dexrazoxane—Ill-defined disorder—Doxorubicin—breast cancer	2.93e-05	0.000173	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—H2AFX—breast cancer	2.93e-05	0.00123	CbGpPWpGaD
Dexrazoxane—Pruritus—Docetaxel—breast cancer	2.92e-05	0.000173	CcSEcCtD
Dexrazoxane—Nervous system disorder—Methotrexate—breast cancer	2.92e-05	0.000172	CcSEcCtD
Dexrazoxane—Anaemia—Doxorubicin—breast cancer	2.92e-05	0.000172	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Methotrexate—breast cancer	2.91e-05	0.000172	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK3—breast cancer	2.91e-05	0.00122	CbGpPWpGaD
Dexrazoxane—Myalgia—Epirubicin—breast cancer	2.91e-05	0.000172	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—E2F1—breast cancer	2.91e-05	0.00122	CbGpPWpGaD
Dexrazoxane—Nausea—Paclitaxel—breast cancer	2.89e-05	0.000171	CcSEcCtD
Dexrazoxane—Skin disorder—Methotrexate—breast cancer	2.89e-05	0.000171	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.89e-05	0.00017	CcSEcCtD
Dexrazoxane—Discomfort—Epirubicin—breast cancer	2.87e-05	0.00017	CcSEcCtD
Dexrazoxane—Asthenia—Capecitabine—breast cancer	2.87e-05	0.000169	CcSEcCtD
Dexrazoxane—Malaise—Doxorubicin—breast cancer	2.85e-05	0.000168	CcSEcCtD
Dexrazoxane—Dry mouth—Epirubicin—breast cancer	2.84e-05	0.000168	CcSEcCtD
Dexrazoxane—Anorexia—Methotrexate—breast cancer	2.84e-05	0.000168	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—breast cancer	2.83e-05	0.00119	CbGpPWpGaD
Dexrazoxane—Syncope—Doxorubicin—breast cancer	2.83e-05	0.000167	CcSEcCtD
Dexrazoxane—Pruritus—Capecitabine—breast cancer	2.83e-05	0.000167	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—breast cancer	2.83e-05	0.00119	CbGpPWpGaD
Dexrazoxane—Leukopenia—Doxorubicin—breast cancer	2.83e-05	0.000167	CcSEcCtD
Dexrazoxane—Diarrhoea—Docetaxel—breast cancer	2.83e-05	0.000167	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK2—breast cancer	2.8e-05	0.00118	CbGpPWpGaD
Dexrazoxane—Loss of consciousness—Doxorubicin—breast cancer	2.78e-05	0.000164	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—breast cancer	2.77e-05	0.00116	CbGpPWpGaD
Dexrazoxane—Infection—Epirubicin—breast cancer	2.77e-05	0.000163	CcSEcCtD
Dexrazoxane—Cough—Doxorubicin—breast cancer	2.76e-05	0.000163	CcSEcCtD
Dexrazoxane—Shock—Epirubicin—breast cancer	2.74e-05	0.000162	CcSEcCtD
Dexrazoxane—Diarrhoea—Capecitabine—breast cancer	2.74e-05	0.000162	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—BIRC5—breast cancer	2.73e-05	0.00115	CbGpPWpGaD
Dexrazoxane—Nervous system disorder—Epirubicin—breast cancer	2.73e-05	0.000161	CcSEcCtD
Dexrazoxane—Dizziness—Docetaxel—breast cancer	2.73e-05	0.000161	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Epirubicin—breast cancer	2.73e-05	0.000161	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Methotrexate—breast cancer	2.71e-05	0.00016	CcSEcCtD
Dexrazoxane—Skin disorder—Epirubicin—breast cancer	2.71e-05	0.00016	CcSEcCtD
Dexrazoxane—Insomnia—Methotrexate—breast cancer	2.69e-05	0.000159	CcSEcCtD
Dexrazoxane—Myalgia—Doxorubicin—breast cancer	2.69e-05	0.000159	CcSEcCtD
Dexrazoxane—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.67e-05	0.000158	CcSEcCtD
Dexrazoxane—Discomfort—Doxorubicin—breast cancer	2.66e-05	0.000157	CcSEcCtD
Dexrazoxane—Anorexia—Epirubicin—breast cancer	2.65e-05	0.000157	CcSEcCtD
Dexrazoxane—Dyspnoea—Methotrexate—breast cancer	2.65e-05	0.000157	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDK4—breast cancer	2.65e-05	0.00111	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TERT—breast cancer	2.65e-05	0.00111	CbGpPWpGaD
Dexrazoxane—Somnolence—Methotrexate—breast cancer	2.65e-05	0.000156	CcSEcCtD
Dexrazoxane—Dizziness—Capecitabine—breast cancer	2.64e-05	0.000156	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—breast cancer	2.64e-05	0.00111	CbGpPWpGaD
Dexrazoxane—Dry mouth—Doxorubicin—breast cancer	2.63e-05	0.000155	CcSEcCtD
Dexrazoxane—Vomiting—Docetaxel—breast cancer	2.63e-05	0.000155	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—breast cancer	2.62e-05	0.0011	CbGpPWpGaD
Dexrazoxane—Decreased appetite—Methotrexate—breast cancer	2.59e-05	0.000153	CcSEcCtD
Dexrazoxane—Headache—Docetaxel—breast cancer	2.59e-05	0.000153	CcSEcCtD
Dexrazoxane—Gastrointestinal disorder—Methotrexate—breast cancer	2.57e-05	0.000152	CcSEcCtD
Dexrazoxane—Fatigue—Methotrexate—breast cancer	2.57e-05	0.000152	CcSEcCtD
Dexrazoxane—Infection—Doxorubicin—breast cancer	2.56e-05	0.000151	CcSEcCtD
Dexrazoxane—Pain—Methotrexate—breast cancer	2.54e-05	0.00015	CcSEcCtD
Dexrazoxane—Vomiting—Capecitabine—breast cancer	2.54e-05	0.00015	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Epirubicin—breast cancer	2.54e-05	0.00015	CcSEcCtD
Dexrazoxane—Shock—Doxorubicin—breast cancer	2.54e-05	0.00015	CcSEcCtD
Dexrazoxane—Nervous system disorder—Doxorubicin—breast cancer	2.53e-05	0.000149	CcSEcCtD
Dexrazoxane—Thrombocytopenia—Doxorubicin—breast cancer	2.52e-05	0.000149	CcSEcCtD
Dexrazoxane—Insomnia—Epirubicin—breast cancer	2.52e-05	0.000149	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK2—breast cancer	2.51e-05	0.00105	CbGpPWpGaD
Dexrazoxane—Headache—Capecitabine—breast cancer	2.5e-05	0.000148	CcSEcCtD
Dexrazoxane—Skin disorder—Doxorubicin—breast cancer	2.5e-05	0.000148	CcSEcCtD
Dexrazoxane—Dyspnoea—Epirubicin—breast cancer	2.48e-05	0.000147	CcSEcCtD
Dexrazoxane—Somnolence—Epirubicin—breast cancer	2.48e-05	0.000146	CcSEcCtD
Dexrazoxane—Anorexia—Doxorubicin—breast cancer	2.46e-05	0.000145	CcSEcCtD
Dexrazoxane—Nausea—Docetaxel—breast cancer	2.45e-05	0.000145	CcSEcCtD
Dexrazoxane—Feeling abnormal—Methotrexate—breast cancer	2.45e-05	0.000145	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Methotrexate—breast cancer	2.43e-05	0.000144	CcSEcCtD
Dexrazoxane—Decreased appetite—Epirubicin—breast cancer	2.42e-05	0.000143	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—PIK3CA—breast cancer	2.41e-05	0.00101	CbGpPWpGaD
Dexrazoxane—Gastrointestinal disorder—Epirubicin—breast cancer	2.4e-05	0.000142	CcSEcCtD
Dexrazoxane—Fatigue—Epirubicin—breast cancer	2.4e-05	0.000142	CcSEcCtD
Dexrazoxane—Pain—Epirubicin—breast cancer	2.38e-05	0.000141	CcSEcCtD
Dexrazoxane—Constipation—Epirubicin—breast cancer	2.38e-05	0.000141	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—ATM—breast cancer	2.38e-05	0.000999	CbGpPWpGaD
Dexrazoxane—Nausea—Capecitabine—breast cancer	2.37e-05	0.00014	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDK4—breast cancer	2.37e-05	0.000995	CbGpPWpGaD
Dexrazoxane—Urticaria—Methotrexate—breast cancer	2.36e-05	0.00014	CcSEcCtD
Dexrazoxane—Body temperature increased—Methotrexate—breast cancer	2.35e-05	0.000139	CcSEcCtD
Dexrazoxane—Abdominal pain—Methotrexate—breast cancer	2.35e-05	0.000139	CcSEcCtD
Dexrazoxane—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.35e-05	0.000139	CcSEcCtD
Dexrazoxane—Insomnia—Doxorubicin—breast cancer	2.33e-05	0.000138	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—breast cancer	2.33e-05	0.000977	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—RB1—breast cancer	2.3e-05	0.000967	CbGpPWpGaD
Dexrazoxane—Dyspnoea—Doxorubicin—breast cancer	2.3e-05	0.000136	CcSEcCtD
Dexrazoxane—Feeling abnormal—Epirubicin—breast cancer	2.3e-05	0.000136	CcSEcCtD
Dexrazoxane—Somnolence—Doxorubicin—breast cancer	2.29e-05	0.000135	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Epirubicin—breast cancer	2.28e-05	0.000135	CcSEcCtD
Dexrazoxane—Decreased appetite—Doxorubicin—breast cancer	2.24e-05	0.000132	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—TP53—breast cancer	2.23e-05	0.000938	CbGpPWpGaD
Dexrazoxane—Gastrointestinal disorder—Doxorubicin—breast cancer	2.22e-05	0.000131	CcSEcCtD
Dexrazoxane—Fatigue—Doxorubicin—breast cancer	2.22e-05	0.000131	CcSEcCtD
Dexrazoxane—Urticaria—Epirubicin—breast cancer	2.21e-05	0.000131	CcSEcCtD
Dexrazoxane—Constipation—Doxorubicin—breast cancer	2.2e-05	0.00013	CcSEcCtD
Dexrazoxane—Pain—Doxorubicin—breast cancer	2.2e-05	0.00013	CcSEcCtD
Dexrazoxane—Abdominal pain—Epirubicin—breast cancer	2.2e-05	0.00013	CcSEcCtD
Dexrazoxane—Body temperature increased—Epirubicin—breast cancer	2.2e-05	0.00013	CcSEcCtD
Dexrazoxane—Asthenia—Methotrexate—breast cancer	2.14e-05	0.000126	CcSEcCtD
Dexrazoxane—Feeling abnormal—Doxorubicin—breast cancer	2.12e-05	0.000125	CcSEcCtD
Dexrazoxane—Gastrointestinal pain—Doxorubicin—breast cancer	2.11e-05	0.000124	CcSEcCtD
Dexrazoxane—Pruritus—Methotrexate—breast cancer	2.11e-05	0.000124	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—RB1—breast cancer	2.06e-05	0.000865	CbGpPWpGaD
Dexrazoxane—Urticaria—Doxorubicin—breast cancer	2.05e-05	0.000121	CcSEcCtD
Dexrazoxane—TOP2A—Circadian rythm related genes—IL6—breast cancer	2.05e-05	0.000859	CbGpPWpGaD
Dexrazoxane—Body temperature increased—Doxorubicin—breast cancer	2.04e-05	0.00012	CcSEcCtD
Dexrazoxane—Abdominal pain—Doxorubicin—breast cancer	2.04e-05	0.00012	CcSEcCtD
Dexrazoxane—Diarrhoea—Methotrexate—breast cancer	2.04e-05	0.00012	CcSEcCtD
Dexrazoxane—Asthenia—Epirubicin—breast cancer	2e-05	0.000118	CcSEcCtD
Dexrazoxane—Pruritus—Epirubicin—breast cancer	1.97e-05	0.000116	CcSEcCtD
Dexrazoxane—Dizziness—Methotrexate—breast cancer	1.97e-05	0.000116	CcSEcCtD
Dexrazoxane—TOP2A—Integrated Pancreatic Cancer Pathway—AKT1—breast cancer	1.97e-05	0.000825	CbGpPWpGaD
Dexrazoxane—Diarrhoea—Epirubicin—breast cancer	1.91e-05	0.000113	CcSEcCtD
Dexrazoxane—Vomiting—Methotrexate—breast cancer	1.89e-05	0.000112	CcSEcCtD
Dexrazoxane—Headache—Methotrexate—breast cancer	1.86e-05	0.00011	CcSEcCtD
Dexrazoxane—Asthenia—Doxorubicin—breast cancer	1.85e-05	0.000109	CcSEcCtD
Dexrazoxane—Dizziness—Epirubicin—breast cancer	1.84e-05	0.000109	CcSEcCtD
Dexrazoxane—Pruritus—Doxorubicin—breast cancer	1.82e-05	0.000108	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1B—breast cancer	1.79e-05	0.000753	CbGpPWpGaD
Dexrazoxane—Vomiting—Epirubicin—breast cancer	1.77e-05	0.000105	CcSEcCtD
Dexrazoxane—Nausea—Methotrexate—breast cancer	1.77e-05	0.000104	CcSEcCtD
Dexrazoxane—Diarrhoea—Doxorubicin—breast cancer	1.76e-05	0.000104	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—MDM2—breast cancer	1.76e-05	0.000737	CbGpPWpGaD
Dexrazoxane—Headache—Epirubicin—breast cancer	1.74e-05	0.000103	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CCND1—breast cancer	1.71e-05	0.000718	CbGpPWpGaD
Dexrazoxane—Dizziness—Doxorubicin—breast cancer	1.7e-05	0.000101	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—CDKN1A—breast cancer	1.65e-05	0.000695	CbGpPWpGaD
Dexrazoxane—Nausea—Epirubicin—breast cancer	1.65e-05	9.77e-05	CcSEcCtD
Dexrazoxane—Vomiting—Doxorubicin—breast cancer	1.64e-05	9.68e-05	CcSEcCtD
Dexrazoxane—Headache—Doxorubicin—breast cancer	1.61e-05	9.54e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1B—breast cancer	1.6e-05	0.000673	CbGpPWpGaD
Dexrazoxane—Nausea—Doxorubicin—breast cancer	1.53e-05	9.04e-05	CcSEcCtD
Dexrazoxane—TOP2A—Cell Cycle—CCND1—breast cancer	1.53e-05	0.000642	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—CDKN1A—breast cancer	1.48e-05	0.000621	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MAPK3—breast cancer	1.41e-05	0.000592	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle, Mitotic—MYC—breast cancer	1.37e-05	0.000576	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MAPK3—breast cancer	1.26e-05	0.00053	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—MYC—breast cancer	1.23e-05	0.000515	CbGpPWpGaD
Dexrazoxane—TOP2A—Cell Cycle—TP53—breast cancer	1.01e-05	0.000423	CbGpPWpGaD
